Register for email alerts and news feeds:
This journal | BMJ Group
rss
Heart 2001;86:661-665; doi:10.1136/heart.86.6.661
Copyright © 2001 BMJ Publishing Group Ltd & British Cardiovascular Society
Heart 2001;86:661-665 ( December )

Cardiovascular medicine

Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue C D Vizzaa, S Sciomera, S Morellib, C Lavallea, P Di Marziob, D Padovania, R Badagliaccaa, A R Vestria, R Naeijec, F Fedelea

a Department of Cardiovascular and Respiratory Sciences, University La Sapienza, Rome, Italy, b Institute of Internal Medicine, University La Sapienza, c Department of Pathophysiology, Erasme University Hospital, Erasme Campus CP 604, 808 Lennik Road, B-1070 Brussels, Belgium

Correspondence to: Dr Naeije rnaeije{at}ulb.ac.be

Accepted 12 July 2001

OBJECTIVE---To evaluate the effects of one year's treatment with beraprost, an orally active prostacyclin analogue, in patients with severe pulmonary hypertension.
PATIENTS---13 patients with severe pulmonary hypertension. This was primary in nine, thromboembolic in three, and caused by Eisenmenger syndrome in one.
METHODS---All patients underwent right heart catheterisation. Mean (SD) right atrial pressure was 5 (3) mm Hg, mean pulmonary artery pressure was 48 (12) mm Hg, cardiac index was 2.6 (0.8) l/min/m2, and mixed venous oxygen saturation was 68 (7)%. Beraprost was started at the dose of 20 µg three to four times a day (1 µg/kg/day), increasing after one month to 40 µg three to four times a day (2 µg/kg/day), with further increases of 20 µg three to four times a day in case of clinical deterioration.
MAIN OUTCOME MEASURES---New York Heart Association (NYHA) functional class, exercise capacity measured by distance walked in six minutes, and systolic pulmonary pressure (by echocardiography) were evaluated at baseline, after one month's treatment, and then every three months for a year.
RESULTS---After the first month of treatment, NYHA class decreased from 3.4 (0.7) to 2.9 (0.7) (p < 0.05), the six minute walking distance increased from 213 (64) to 276 (101) m (p < 0.05), and systolic pulmonary artery pressure decreased from 93 (15) to 85 (18) mm Hg (NS). One patient died after 40 days from refractory right heart failure, and another was lost for follow up at six months. The 11 remaining patients had persistent improvements in functional class and exercise capacity and a significant decrease in systolic pulmonary artery pressure in the period from 1-12 months. Side effects were minor.
CONCLUSIONS---Oral administration of beraprost may result in long lasting clinical and haemodynamic improvements in patients with severe pulmonary hypertension.


Keywords: pulmonary arterial hypertension; prostacyclin; beraprost

© 2001 by Heart
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Boutet, K., Montani, D., Jais, X., Yaici, A., Sitbon, O., Simonneau, G., Humbert, M. (2008). Review: Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis 2: 249-265 [Abstract]  
  • Shen, J., He, B., Wang, B. (2005). Effects of Lipo-Prostaglandin E1 on Pulmonary Hemodynamics and Clinical Outcomes in Patients With Pulmonary Arterial Hypertension. Chest 128: 714-719 [Abstract] [Full Text]  
  • Post, M.C., Janssens, S., Van de Werf, F., Budts, W. (2004). Responsiveness to inhaled nitric oxide is a predictor for mid-term survival in adult patients with congenital heart defects and pulmonary arterial hypertension. Eur Heart J 25: 1651-1656 [Abstract] [Full Text]  
  • Mukerjee, D., St. George, D., Knight, C., Davar, J., Wells, A. U., Du Bois, R. M., Black, C. M., Coghlan, J. G. (2004). Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 43: 461-466 [Abstract] [Full Text]  
  • Emmel, M, Keuth, B, Schickendantz, S (2004). Paradoxical increase of pulmonary vascular resistance during testing of inhaled iloprost. Heart 90: e2-2 [Abstract] [Full Text]  
  • WILKINS, M. R, WHARTON, J. (2001). Progress in, and future prospects for, the treatment of primary pulmonary hypertension. Heart 86: 603-604 [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Show me all >>